The MHRA has accepted Belite Bio’s application for Tinlarebant to treat Stargardt disease based on Phase 3 DRAGON trial results. Final data expected in Q4 2025. The trial enrolled 104 subjects across 11 countries, evaluating the safety and efficacy of Tinlarebant. Tinlarebant aims to reduce vitamin A-based toxins in the eye. It has received designations in the U.S., Europe, and Japan. Belite Bio is focused on developing therapies for retinal diseases. The Company looks forward to advancing Tinlarebant towards potential global approvals. Forward-looking statements caution about the potential risks and factors affecting Belite Bio’s drug candidates.

Read more at GlobeNewswire: Belite Bio Announces UK’s Medicines and Healthcare Products